

Proinflammatory Markers, Insulin Sensitivity, and Cardiometabolic Risk Factors in Treated HIV Infection

[Q1] Katherine Samaras^{1,2}, S.K. Gan^{1,3}, P. Peake⁴, A. Carr¹ and L.V. Campbell^{1,2}

[Q2] Treated HIV infection and HIV-lipoatrophy increases risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Circulating inflammatory molecules may, in part, explain this increased risk. This study examined circulating inflammatory molecules in treated HIV infection in relation to insulin sensitivity, lipids total body, and intramyocellular fat, compared to insulin-resistant obesity (an index group at high risk of diabetes). Detailed metabolic phenotypes were measured in 20 treated HIV-infected men (with and without subcutaneous lipoatrophy) vs. 26 insulin-resistant obese men (IR-O, $n = 26$), including inflammatory molecules, insulin sensitivity, total body fat (TBF), visceral fat (visceral adipose tissue (VAT)), and intramyocellular lipid (IMCL). C-reactive protein (CRP) levels in treated HIV were similar to those in IR-O, despite lower TBF and greater insulin sensitivity in treated HIV. In HIV-lipoatrophy, CRP was higher than that found in IR-O. Adiponectin was similar between treated HIV and IR-O, but significantly lower in those with HIV-lipoatrophy. In treated HIV, subjects with higher CRP had significantly higher total cholesterol, VAT, and IMCL. In treated HIV, subjects with lower adiponectin had significantly lower HDL and higher triglycerides, glucose, VAT, and IMCL. A proinflammatory milieu equivalent to that of insulin-resistant obesity characterizes lean men with treated HIV infection, worse in those with subcutaneous lipoatrophy. These factors may contribute to the accelerated diabetogenesis and cardiac risk observed in treated HIV infection.

Obesity (2008); doi:10.1038/oby.2008.500

INTRODUCTION

Treatment of HIV with highly active antiretroviral therapy (HAART) increases the risk for cardiovascular disease (CVD) (1,2) and type 2 diabetes mellitus (T2DM) (3,4). Recent studies have found the relative risk of myocardial infarction in HIV-infected patients to be almost doubled after adjustment for traditional risk factors (2). The large Data Collection on Adverse Events of Anti-HIV Drugs study recently estimated the risk of myocardial infarction following HAART-initiation at 16% per annum (1). Disorders of glucose metabolism have been reported at 23% after only 2 years of protease inhibitor therapy (3) and recent studies have reported a fourfold increase in T2DM risk in HIV-infected HAART recipients (4). HAART in HIV infection produces widespread metabolic complications, including hyperlipidemia, insulin resistance, lipodystrophy (LD) (peripheral fat wasting (lipoatrophy) with abdominal/visceral fat accumulation (lipohypertrophy)), and disturbances in adipokines (5–18). The role of circulating proinflammatory molecules within this accelerated paradigm of CVD and T2DM development requires further investigation.

There is increasing recognition that adipose tissue and disturbed adipocyte physiology contribute to the inflammatory milieu. C-reactive protein (CRP) levels are strongly associated with adipose tissue mass (19) and predict CVD (20,21) and T2DM (22–24). Low adiponectin is associated with visceral obesity and predicts CVD (25) and T2DM (26). Other proinflammatory adipocyte products such as interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α) are also implicated.

In the most significant and possibly irreversible HAART metabolic complication, lipoatrophy, disturbed adipocyte function may exacerbate preexisting insulin resistance (6), hyperlipidemia and contributes to metabolic syndrome (27–29). In this patient group, we have previously shown that LD (lipoatrophy with abdominal lipohypertrophy) is associated with disturbed glucose metabolism, reduced insulin action, intramyocellular triglyceride accumulation (6), and low adiponectin (27). Disturbed secretion of other adipocyte-derived proinflammatory molecules in treated HIV infection may also contribute to systemic inflammation and its consequences.

This study examined markers of systemic inflammation in HIV-infected men receiving HAART with and without LD

¹St Vincent's Hospital, Darlinghurst, New South Wales, Australia; ²Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia;

³School of Medicine and Pharmacology, Royal Perth Hospital, Perth, Western Australia, Australia; ⁴Prince of Wales Hospital, Randwick, New South Wales, Australia.

Correspondence: Katherine Samaras (k.samaras@garvan.org.au)

Received 30 December 2007; accepted 17 June 2008; advance online publication 00 Month 2008. doi:10.1038/oby.2008.500

(lipoatrophy with abdominal lipohypertrophy), compared to fat-free mass-matched men with insulin-resistant obesity, a risk group predisposed to CVD and T2DM, with reference to cardiovascular risk factors and markers of disturbed insulin action (insulin sensitivity and intramyocellular lipids (IMCLs)).

METHODS AND PROCEDURES

All subjects were male. There were 20 HIV-infected HAART recipients ($n = 10$ with clinically evident LD (lipoatrophy with abdominal lipohypertrophy) (HIV+LD) and $n = 10$ without (HIV+)), recruited from a major urban teaching hospital HIV ambulatory care clinic. HIV-infected subjects with LD were matched to those without, for: known duration of HIV infection (HIV+LD: 9.9 ± 1 years vs. HIV+: 7.7 ± 1.5 years, $P = 0.24$), CD4 count ($\times 10^5/l$) (HIV+LD: 493 ± 88 vs. HIV+: 392 ± 102 , $P = 0.46$) and HIV viral load (log copies/ml plasma) (HIV+LD: 3.3 ± 0.3 vs. HIV+: 3.2 ± 0.3 , $P = 0.94$). There were differences in HAART drug use between the HIV groups: all subjects with HIV+LD had current use of protease inhibitors (vs. none in HIV+); there was roughly equivalent use of nucleoside reverse transcriptase inhibitors: HIV+LD: lamivudine ($n = 8$), stavudine ($n = 5$), zidovudine ($n = 3$), abacavir ($n = 1$), didanosine ($n = 1$); HIV+: lamivudine ($n = 6$), stavudine ($n = 2$), zidovudine ($n = 3$), didanosine ($n = 1$). There were differences in nonnucleoside reverse transcriptase inhibitor use: HIV+LD: efavirenz ($n = 1$); HIV+: nevirapine ($n = 5$). The presence of peripheral lipoatrophy was determined by clinical examination, as described (3).

The control group consisted of $n = 26$ HIV-negative insulin-resistant and obese men (IR-O). The IR-O group consisted of a subgroup of obese, sedentary but otherwise healthy men recruited for an exercise metabolic study; controls were matched to the HIV-infected subjects for age and fat-free mass. Insulin action in the obese control group was determined by glucose infusion rate under hyperinsulinemic conditions, adjusted for fat-free mass, using a median infusion rate of $37.1 \mu\text{mol/kg fat-free mass}\cdot\text{min}$, as we have previously published (30). A single investigator performed matching of subjects after determination of study hypotheses, statistical plan and prior to any analyses.

No subjects were receiving lipid lowering or diabetic medications. The St Vincent's Hospital Research Ethics Committee approved study protocols and all subjects gave written, informed consent.

Anthropometric measures included: weight (nearest 0.1 kg), height by stadiometer (nearest 0.01 m), waist and hip circumferences (nearest 0.01 m); waist was defined as the narrowest point between the lowest rib and the iliac crest, hip at the level of the greater trochanter.

Total body fat (TBF) and fat-free mass were measured by dual-energy X-ray absorptiometry (Lunar DXPL, Madison, WI). Regional fat was measured in limbs (arms plus legs), trunk and central abdominal fat, which was defined as a 9.8 cm vertical height window from the top of the iliac crest, extending laterally to the inner aspect of the costal margin.

Visceral adipose and subcutaneous adipose tissue (VAT and SAT, respectively) were measured with multiple slices using magnetic resonance imaging. 12 T-1 weighted axial slices (each 0.5 mm) were taken at 0.5 mm intervals between the levels of the L1-2 and L4-5 intervertebral discs. VAT (intraabdominal) and SAT were quantified using planimetric analysis (NIH Image 1.62; National institutes of Health, Bethesda, MD). Volumes of VAT and SAT were derived from interpolation between scanned slices.

IMCL was determined using a 1.5 Tesla medical magnetic resonance scanner (General Electric, Milwaukee, WI) after an 8-h overnight fast, having avoided strenuous physical activity in the preceding 5 days. An extremity coil was used to scan the right lower leg in each subject. A $2.0 \times 2.0 \times 2.0$ cm voxel was positioned within the soleus muscle, with acquisition of spectra by point-resolved spectroscopy sequence, echo time 135 ms, repetition time 1,500 ms.

Insulin-stimulated glucose disposal was measured using the euglycemic hyperinsulinemic clamp, following a 10-h overnight fast. Bilateral forearm vein cannulation was undertaken: one retrograde

with arterialization for blood collection, the other for infusion of insulin and glucose. Insulin was infused at $2 \text{ mU}\cdot\text{min}^{-1}\cdot\text{kg}/\text{total body mass}$ for 150 min, to suppress hepatic glucose production and reflect predominantly muscle insulin-stimulated glucose disposal, as previously described (6). Plasma glucose was measured at 10-min intervals with adjustment of the glucose infusion rate to maintain a plasma glucose level of 5.0 mmol/l (YSI 2300 StatPlus; YSI, Yellow Springs, OH). Whole body insulin sensitivity was measured by the glucose infusion rate at steady state, calculated from the last 40 min of the clamp and expressed per fat-free mass from the dual-energy X-ray absorptiometry measurement.

All assays samples were collected after an overnight fast of 12 h. Biochemical analyses: insulin, leptin, adiponectin by radioimmunoassay (Linco Research, St Charles, MO); CRP by a highly sensitive assay, using a Dade Behring Dimension RxL Chemistry Analyzer with reagents and calibrators supplied by Dade Behring Diagnostics (Sydney, New South Wales, Australia) (31); IL-6 and TNF- α by immunoassay by R&D Systems (Minneapolis, MN).

Statistical analyses

Data were analyzed using StatView 4.55 (SAS Institute, Cary, NC). Results were expressed as mean \pm s.e. Group comparisons were made using ANOVA, with Fisher's PLSD multiple regression analyses (Q4) included highly related variables. Models were constructed to determine whether the strong relationships between insulin sensitivity and the variables of adipokines, inflammatory factors were exclusive of the close relationships with body and visceral fat.

RESULTS

Insulin-resistant obese HIV-negative controls (IR-O) had a higher BMI than HIV-infected subjects though, importantly fat-free mass was similar between all groups (Table 1).

Inflammatory markers and adipokines

CRP, adiponectin, TNF- α , and IL-6 in HIV-infected HAART recipients were similar to that found in insulin-resistant obesity (Table 1). Leptin was significantly lower in HIV-infected HAART recipients (Table 1).

The presence of LD in HIV-infected HAART recipients (HIV+LD) was associated with significantly higher CRP and lower adiponectin and leptin compared to insulin-resistant obesity (Table 1, Figure 1). In HIV+LD, adiponectin was also significantly lower than that found in treated HIV without LD (Table 1, Figure 1). There were no relationships between CRP, adiponectin, TNF- α and IL-6 with CD4 count or viral load (data not shown).

Cardiovascular risk factors, insulin action and IMCL

Overall, HIV-infected HAART recipients had similar cardiovascular risk factors to insulin-resistant obesity, for fasting total cholesterol, triglycerides, apolipoprotein B, and glucose (Table 1). HIV-HAART without LD was associated with higher HDL and lower fasting glucose than insulin-resistant obesity (Table 1), whereas in HIV+LD, all lipid parameters were similar to insulin-resistant obesity (Table 1).

HIV-infected HAART recipients were more insulin sensitive with less IMCL compared to insulin-resistant obesity (Table 1). The presence of LD in HIV-infected HAART recipients was associated with similar insulin sensitivity and IMCL to insulin-resistant obesity (Table 1).

Body fat partitioning and impact on CRP and adiponectin

Despite matching for fat-free mass, HIV-infected HAART recipients as a group had lower TBF, fat, and SAT but similar VAT and higher VAT:SAT, compared to insulin-resistant obese (Table 1). Similarly, HIV+LD had lower total body and limb fat, lower SAT, similar VAT and a higher VAT:SAT, compared to insulin-resistant obesity, although the differences were more marked (Table 1). In subgroup analyses, HIV-infected subjects without LD had significantly lower VAT compared to controls, though VAT:SAT was similar (Table 1).

Because treated HIV infection had both significantly lower %TBF and higher VAT:SAT than IR-O, analyses was undertaken of CRP and adiponectin adjusted for %TBF and VAT:SAT, to determine whether the differences observed in inflammatory markers were independent of differences in TBF. CRP remained higher in treated HIV infection vs. IR-O after adjustment for %TBF ($P = 0.001$) and VAT:SAT ($P = 0.04$). Adiponectin remained lower in treated HIV infection

compared to IR-O after adjustment for %TBF ($P = 0.0001$) and VAT:SAT ($P = 0.007$).

Tertile analyses

Tertile analyses were performed in HIV-infected HAART recipients. Subjects in the highest CRP tertile had significantly higher total cholesterol, %body fat, VAT, IMCL, compared to the lowest CRP tertile (Table 2). Subjects in the lowest adiponectin tertile had significantly higher triglycerides, glucose, insulin, VAT and IMCL, and lower HDL cholesterol (Table 3). Insulin sensitivity (glucose infusion rate expressed per kg lean tissue mass) was not significantly different between low and high adiponectin tertiles (Table 3).

Multiple regression analyses

Models were constructed to evaluate the contribution of adipokines and adipose tissue mass to variance in insulin sensitivity, fasting glucose, cardiometabolic risk factors. Insulin


Table 1 Characteristics of treated HIV-infected subjects, compared to insulin-resistant obese subjects

| | Insulin-resistant obesity (N = 26) | All treated HIV infection (N = 20) | Treated HIV, no LD (N = 10) | Treated HIV with LD (N = 10) |
|--|---------------------------------------|---------------------------------------|--------------------------------|---------------------------------|
| Age (years) | 39.0 ± 1.2 | 43.2 ± 2.0 | 42.1 ± 2.7 | 44.4 ± 3.2 |
| BMI (kg/m ²) | 29.6 ± 0.76 | 24.6 ± 1.0*** | 25.4 ± 1.6 ^{††} | 23.9 ± 1.3 ^{†††} |
| Inflammatory markers | | | | |
| C-reactive protein (mg/l) | 3.4 ± 0.3 | 4.6 ± 0.7 | 3.6 ± 0.5 | 5.5 ± 1.1 [†] |
| Adiponectin (µg/ml) | 7.5 ± 0.8 | 7.2 ± 0.8 | 9.7 ± 0.9 | 4.7 ± 0.9 ^{†††§} |
| TNF-α (pg/ml) | 0.08 ± 0.01 | 0.09 ± 0.03 | 0.12 ± 0.05 | 0.06 ± 0.02 |
| IL-6 (pg/ml) | 1.0 ± 0.3 | 1.2 ± 0.6 | 1.6 ± 1.2 | 0.87 ± 0.3 |
| Leptin | 6.2 ± 0.5 | 3.5 ± 0.8** | 4.3 ± 1.4 | 2.2 ± 0.7 ^{††} |
| Cardiometabolic risk factors | | | | |
| Total cholesterol (mmol/l) | 4.7 ± 0.2 | 4.5 ± 0.2 | 4.3 ± 0.3 | 4.8 ± 0.3 |
| HDL cholesterol (mmol/l) | 0.9 ± 0.05 | 1.0 ± 0.05 | 1.1 ± 0.07 [†] | 0.9 ± 0.05 |
| Triglycerides (mmol/l) | 1.9 ± 0.4 | 2.2 ± 0.4 | 1.6 ± 0.5 | 2.9 ± 0.5 |
| Glucose (mmol/l) | 5.7 ± 0.1 | 5.4 ± 0.2 | 5.2 ± 0.2 [†] | 5.5 ± 0.2 |
| Insulin (mU/l) | 14.0 ± 1.4 | 12.8 ± 2.0 | 10.9 ± 3.5 | 14.7 ± 1.8 |
| Glucose infusion rate (µmol/min/kg fat-free mass) | 39.5 ± 2.9 | 51.8 ± 5.1* | 66.8 ± 6.5 ^{†††} | 36.7 ± 4.2 |
| Intramyocellular lipid (see below) | 0.019 ± 0.001 | 0.016 ± 0.001* | 0.012 ± 0.002 ^{†††} | 0.019 ± 0.002 |
| Body composition | | | | |
| Weight (kg) | 90.5 ± 2.3 | 77.6 ± 2.9*** | 80.0 ± 4.4 [†] | 75.3 ± 4.0 ^{††} |
| Total body fat (kg) | 29.81 ± 1.62 | 17.05 ± 2.25*** | 19.83 ± 3.64 ^{††} | 14.27 ± 2.54 ^{†††} |
| % Total body fat | 32.3 ± 1.3 | 20.8 ± 1.9*** | 23.4 ± 2.9 ^{††} | 18.1 ± 2.6 ^{†††} |
| Limb fat (kg) | 11.96 ± 0.71 | 6.62 ± 1.03*** | 9.01 ± 1.63 [†] | 4.24 ± 0.75 ^{†††} |
| % Limb fat | 30.0 ± 1.4 | 19.1 ± 2.1*** | 24.4 ± 2.9 | 13.7 ± 2.1 ^{†††} |
| VAT | 1.51 ± 0.10 | 1.25 ± 0.18 | 1.00 ± 0.19 [†] | 1.49 ± 0.29 |
| SAT | 2.79 ± 0.22 | 1.51 ± 0.24*** | 1.77 ± 0.43 [†] | 1.26 ± 0.22 ^{†††} |
| VAT:SAT | 0.59 ± 0.04 | 0.93 ± 0.13** | 0.61 ± 0.08 | 1.25 ± 0.21 ^{††} |

All data are expressed as mean ± s.e.m. Intramyocellular lipid was quantified as a percentage of the water resonance peak area (see Methods and Procedures).

HDL, high-density lipoprotein; IL-6, interleukin-6; SAT, subcutaneous adipose tissue; TNF-α, tumor necrosis factor-α; VAT, visceral adipose tissue.

Control vs. HIV-infected: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$. Control vs. HIV, no LD: [†] $P < 0.05$, ^{††} $P < 0.01$, ^{†††} $P < 0.005$. Control vs. HIV+LD: [†] $P < 0.05$, ^{††} $P < 0.01$, ^{†††} $P < 0.005$. HIV no LD vs. HIV+LD: [§] $P < 0.005$.



[Q5] **Figure 1** C-reactive protein and adiponectin in treated HIV infection with- and without lipodystrophy, compared to insulin-resistant obesity. * $P < 0.05$, ** $P < 0.005$.

Table 2 C-reactive protein is associated with higher total cholesterol, total body fat, and intramyocellular lipid in treated HIV infection

| | Top tertile (5.85–13.1 mg/l) <i>n</i> = 7 | Low tertile (1.92–2.47 mg/l) <i>n</i> = 7 | <i>P</i> |
|------------------------------------|---|---|----------|
| C-reactive protein (mg/l) | 7.93 ± 1.00 | 2.21 ± 0.15 | 0.0001 |
| Total cholesterol (mmol/l) | 5.2 ± 0.38 | 3.9 ± 0.21 | 0.01 |
| Triglycerides (mmol/l) | 3.1 ± 0.9 | 1.3 ± 0.3 | 0.08 |
| HDL cholesterol (mmol/l) | 0.96 ± 0.09 | 0.93 ± 0.12 | 0.85 |
| Apolipoprotein B (mmol/l) | 1.14 ± 0.11 | 0.89 ± 0.06 | 0.07 |
| Total body fat (%) | 26.9 ± 4.3 | 15.2 ± 1.1 | 0.02 |
| Limb fat (%) | 24.4 ± 5.1 | 14.9 ± 1.6 | 0.10 |
| VAT | 1.96 ± 0.29 | 0.62 ± 0.07 | 0.0008 |
| VAT:SAT | 1.27 ± 0.32 | 0.66 ± 0.06 | 0.08 |
| Soleus IMCL ^a | 0.019 ± 0.002 | 0.011 ± 0.001 | 0.004 |
| Glucose (mmol/l) | 5.7 ± 0.27 | 5.5 ± 0.24 | 0.74 |
| Insulin (mU/l) | 16.2 ± 4.4 | 11.1 ± 2.6 | 0.36 |
| Glucose infusion rate ^b | 42.3 ± 10.1 | 55.0 ± 7.1 | 0.33 |
| Adiponectin (µg/ml) | 5.6 ± 1.3 | 8.5 ± 1.6 | 0.18 |
| IL-6 (pg/ml) | 2.7 ± 1.7 | 0.40 ± 0.3 | 0.21 |
| TNF-α (pg/ml) | 0.09 ± 0.05 | 0.03 ± 0.01 | 0.23 |

HDL, high-density lipoprotein; IL-6, interleukin-6; IMCL, intramyocellular lipid; SAT, subcutaneous adipose tissue; TNF-α, tumor necrosis factor-α; VAT, visceral adipose tissue.
^aIntramyocellular lipid was quantified as a percentage of the water resonance peak area (see Methods and Procedures). ^bµmol/min/kg fat-free mass.

action was best predicted by a model including adiponectin and TNF-α, explaining 62% of the variance ($P = 0.0004$); addition of IMCL increased the predictive value of the model to 75% ($P < 0.0001$); addition of IL-6, CRP, %TBF or VAT did not

Table 3 Low total adiponectin is associated with higher total cholesterol, total body fat, and intramyocellular lipid in treated HIV infection

| | Top tertile (5.85–13.1 mg/l) <i>n</i> = 7 | Low tertile (1.92–2.47 mg/l) <i>n</i> = 7 | <i>P</i> |
|----------------------------|---|---|----------|
| Adiponectin (µg/ml) | 11.3 ± 0.77 | 3.5 ± 0.71 | 0.0001 |
| Total cholesterol (mmol/l) | 4.3 ± 0.4 | 4.9 ± 0.4 | 0.29 |
| Triglycerides (mmol/l) | 1.0 ± 0.2 | 2.9 ± 0.7 | 0.03 |
| HDL cholesterol (mmol/l) | 1.11 ± 0.1 | 0.84 ± 0.07 | 0.03 |
| Apolipoprotein B (mmol/l) | 0.87 ± 0.06 | 1.15 ± 0.10 | 0.03 |
| Total body fat (%) | 18.8 ± 2.6 | 17.1 ± 1.7 | 0.58 |
| Limb fat (%) | 20.7 ± 3.3 | 13.1 ± 1.8 | 0.06 |
| VAT | 0.64 ± 0.09 | 1.52 ± 0.30 | 0.02 |
| VAT:SAT | 0.52 ± 0.04 | 1.33 ± 0.29 | 0.02 |
| Soleus IMCL | 0.010 ± 0.001 | 0.020 ± 0.002 | 0.0003 |
| Glucose (mmol/l) | 5.05 ± 0.04 | 5.96 ± 0.13 | <0.0001 |
| Insulin (units) | 8.4 ± 1.0 | 15.7 ± 2.5 | 0.03 |
| Glucose infusion rate | 42.3 ± 10.1 | 55.0 ± 7.1 | 0.33 |
| C-reactive protein (mg/l) | 3.2 ± 0.5 | 6.1 ± 1.6 | 0.11 |
| IL-6 (pg/ml) | 0.31 ± 0.17 | 10.2 ± 0.34 | 0.09 |
| TNF-α (pg/ml) | 0.11 ± 0.06 | 0.05 ± 0.02 | 0.39 |

Intramyocellular lipid was quantified as a percentage of the water resonance peak area (see Methods and Procedures).

HDL, high-density lipoprotein; IL-6, interleukin-6; SAT, subcutaneous adipose tissue; TNF-α, tumor necrosis factor-α; VAT, visceral adipose tissue.

improve the model; removal of TNF-α weakened the model by 9%. Fasting glucose was not predicted by a regression model containing adiponectin, CRP, TNF-α, and IL-6. Total cholesterol was predicted by a model containing triglyceride, visceral fat, CRP, and IL-6, explaining 61% of the variance ($P = 0.005$); addition of adiponectin or TNF-α did not strengthen the model. For HDL cholesterol, a model containing adiponectin, IL-6 and CRP explained 64% of its variance ($P = 0.001$); addition of visceral fat and insulin sensitivity did not improve the model. For triglycerides, 63% of the variance was explained by a model containing visceral fat, IL-6, CRP, and adiponectin ($P = 0.003$). For CRP, 62% of its variance was explained by a model containing visceral fat, total cholesterol, triglycerides, and IL-6 ($P = 0.004$); adding adiponectin, TNF-α, %TBF, or insulin sensitivity did not strengthen the model. For hypoadiponectinemia, 39% of the variance was explained by a model containing insulin sensitivity and CRP ($P = 0.0001$); addition of TNF-α, IL-6 or any measure of body lipid store (%TBF, VAT, or IMCL) did not strengthen the model.

DISCUSSION

This study examined adipokines involved in inflammation in relation to insulin sensitivity, lipid partitioning and cardiovascular risk factors in HIV-infected HAART recipients with and without LD, compared to insulin-resistant obesity, as an index group at high risk of both T2DM and CVD. We found that subjects with treated HIV infection had an inflammatory profile

equivalent to that found in insulin-resistant obesity, despite lower body fat. HIV-infected subjects with LD had evidence of greater systemic inflammation than that seen in insulin-resistant obesity with higher CRP and more pronounced hypo adiponectinemia. Regression models indicated insulin sensitivity was best predicted by adiponectin and TNF- α , but not body fat partitioning. In contrast, adipokine levels and body fat partitioning contributed to the variance in fasting lipids.

Proinflammatory adipokine disturbances in treated HIV infection may affect the generation of atheroma and impaired glucose metabolism, contributing to the increased cardiovascular risk observed in prospective studies. The regulatory roles of these circulating factors in the generation of atheroma and glucose disturbances under usual conditions are the focus of intense investigation. In the circumstances of treated HIV infection, less is understood. Prospective observational studies have documented higher rates of both myocardial infarction and T2DM. The most recent data from the Data Collection on Adverse Events of Anti-HIV Drugs study of over 23,000 HIV-infected patients, report a 16% increased risk of myocardial infarction per year of exposure to one HAART drug class, protease inhibitors (1). This effect was independent of serum lipids (1); suggesting risk may be mediated by other mechanisms. A further study indicated a 75% increase in the risk of myocardial infarction in treated HIV infection, compared to a noninfected cohort, after adjustment for age, gender, race, hypertension, diabetes, and dyslipidemia (2). Higher risk for T2DM in HIV-infected HAART recipients have been reported: we found prevalence rates of 7 and 16% for T2DM and impaired glucose tolerance, respectively, after 2 years of protease inhibitor therapy in a relatively young, nonobese cohort (3). More recently, Brown *et al.* reported a 10% incidence of T2DM in HIV-infected HAART recipients >4 years, compared to 3% in age- and BMI-matched HIV-negative controls (4). HAART-induced disturbances in lipids, insulin resistance and inflammation obviously contribute to the development of atheroma and diabetes in HIV infection treated with HAART.

CRP is recognized to predict coronary disease and is a marker of low-grade systemic inflammation (32,33). Adipose tissue and the liver produce CRP; circulating levels are predicted by adiposity (19). Our study found CRP levels were significantly higher in lipodystrophic subjects, despite much lower levels of TBF, suggestive of dysregulated adipocyte and hepatic hypersecretion of this inflammatory marker. However, the increased visceral obesity found in lipodystrophic subjects may contribute to higher CRP found. Our results concur with other studies finding higher CRP levels in HIV-infected women, which were associated with central adiposity (estimated by waist-to-hip ratio) (34).

This study also found adiponectin in HIV-infected HAART recipients was similar to that found in insulin-resistant obesity; hypo adiponectinemia was more pronounced if LD was present. Adiponectin is an antiatherogenic, antidiabetic adipokine. Hypo adiponectinemia is found in obesity, insulin resistance, metabolic syndrome, and diabetes and identifies individuals at higher risk of myocardial infarction (25). We have previously

reported that the inverse relationship between adiponectin and insulin action is independent of circulating, visceral and IMCL (35), suggesting nonlipid pathways may be responsible for the insulin-sensitizing effects of adiponectin. In this study, regression models of insulin sensitivity suggested primacy for adiponectin, as models were not improved by the inclusion of total body or visceral fat or other inflammatory molecules. Hypo adiponectinemia has previously been reported in treated HIV-infected HAART recipients with LD (36–39) and metabolic syndrome (27). Our results concur with prior reports of low adiponectin following adjustment for fat mass (36). The synthesis of published studies to date, suggest HIV-infected HAART recipients have disturbances in adipocyte physiology that result in reduced adiponectin secretion. Our study suggests the disturbance is similar to that found in insulin-resistant obesity, but more profound in the presence of LD.

TNF- α and IL-6 are elevated in obesity, insulin resistance, and diabetes (40,41). In this study, TNF- α did modestly strengthen multivariate models predicting insulin sensitivity. Activation of the TNF system in lipodystrophic HIV-infected HAART recipients has been reported, with increased soluble TNF- α receptor 2 levels (42). Elegant studies of SAT explants in culture have demonstrated increased TNF- α and soluble TNF- α receptor 2 secretion in lipodystrophic HIV-infected HAART recipients (43). TNF- α and IL-6 mRNA expression are increased in peripheral adipocytes from lipodystrophic HIV-infected HAART recipients with expression levels relating to macrophage infiltration (43). IL-6 increases secretion of CRP from both adipocytes and the liver. It is of interest that our multivariate models of adipokines found IL-6 predicted the traditional cardiovascular risk factors of total cholesterol, HDL cholesterol, triglycerides, and CRP.

One of the strengths of this study is matching between the treated HIV groups and control group for fat-free mass, using measures of body composition by dual-energy X-ray absorptiometry. Further strengths include detailed *in vivo* measures including insulin action by hyperinsulinemic euglycemic clamp and IMCL by magnetic resonance spectroscopy. Our control group was selected for insulin resistance and central obesity; insulin action (glucose infusion rate adjusted for fat-free mass—GIR) was similar to that found in other studies of overweight men (35). This GIR is less than that we have found in our prior studies of lean healthy controls show a wide variation in insulin action, with mean GIR 72 $\mu\text{mol}/\text{min}/\text{kg}$ fat-free mass (range 52–95 $\mu\text{mol}/\text{min}/\text{kg}$ fat-free mass) (44). Limitations of this study include the cross-sectional nature of the study and the relatively small numbers of subjects studied, which may have reduced the power of the study to detect differences. Detailed metabolic studies such as we have performed with hyperinsulinemic clamp, spectroscopy, and magnetic resonance are not feasible in larger cohorts however. Simpler surrogate measures (where possible) introduce error and imprecision. A further group of insulin-sensitive fat-free matched men would have provided additional information of inflammatory markers in health for comparison, but was not possible in this study. The cross-sectional nature of the study

does not allow conclusions regarding whether the disturbances noted are because of primary drug effects or secondary to drug-induced complications. Our results may also have been confounded by nonmeasured factors. Prospective studies would assist in this regard. This study was also limited to white men, reflecting the demographics of HIV infection in Australia. Study findings can thus not be extrapolated to women or other ethnic groups. Further, the composition of HAART regimens have changed substantially in recent times and new drug classes (entry inhibitors and integrase inhibitors) currently being evaluated, may alter the face of HAART and its complications. Little or no metabolic data are available for these new classes.

The findings of elevated CRP and hypoadiponectinemia are suggestive of functional impairments in the synthesis or secretion of adipocyte-derived products in HIV-associated LD. In concert with the associations of higher lipids and lipid partitioning (doubled IMCL), these could be expected to promote atherogenesis and contribute to the increased cardiovascular risk found in treated HIV infection. The pathogenetic mechanisms are unclear; “lipotoxic” effects of circulating lipid, visceral obesity, ectopic fat deposition, and IMCL, are only part of the disturbed physiology in association with insulin resistance. Adipokines and inflammatory markers may exert independent effects on atherogenesis, or act through other intermediaries. It has been hypothesized that the reconstitution of the immune response with the instigation of HAART in HIV infection may contribute to the disturbances in inflammatory markers (43). This interesting hypothesis may be extended to encompass the potential adverse effects of adipocyte-derived molecules on atherogenesis. HIV-associated LD may induce a proinflammatory acute-phase responsiveness, marked by higher CRP and lower adiponectin in the setting of higher lipids. In the already metabolically adverse setting of visceral adiposity and insulin resistance, these may accelerate adverse cardiometabolic risk. Prospective studies of HIV-infected patients commencing HAART will assist our understanding of the inflammatory and adipokine disturbances observed in this study and, importantly, give insights into the time course and onset of inflammation, dyslipidemia, insulin resistance, and body fat partitioning. Furthermore, understanding the pathophysiology of treated HIV infection and LD would shed light on the inflammatory changes described in atheroma, T2DM, and obesity.

ACKNOWLEDGMENTS

K.S. is a recipient of a RD Wright Career Development Award, National Health and Medical Research Council, Australian Government. This study was supported in part by a Royal Australasian College of Physicians—Diabetes Australia Fellowship and by the National Health and Medical Research Council.

DISCLOSURE

[Q6] The authors declared no conflict of interest.

© 2008 The Obesity Society

REFERENCES

- DAD Study group, Friis-Møller N, Reiss P *et al.* Class of antiretroviral drugs and risk of myocardial infarction. *N Engl J Med* 2007;356:1632–1641.
- Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. *J Clin Endocrinol Metab* 2007;92:2506–2512.
- Carr A, Samaras K, Thorisdottir A *et al.* Natural history, diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy, hyperlipidaemia and diabetes mellitus. *Lancet* 1999;353:2094–2099.
- Brown TT, Cole SR, Li X *et al.* Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the mUlticenter AIDS cohort study. *Arch Intern Med* 2005;165:1179–1184.
- Carr A, Samaras K, Burton S *et al.* A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. *AIDS* 1998;12:F51–F58.
- Gan SK, Samaras K, Thompson CH *et al.* Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. *Diabetes* 2002;51:3163–3169.
- Hadigan C, Meigs JB, Corcoran C *et al.* Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. *Clin Infect Dis* 2001;32:130–139.
- Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. *N Engl J Med* 2005;352:48–62.
- Friis-Møller N, Weber R, Reiss P *et al.* Cardiovascular risk factors in HIV patients: association with antiretroviral therapy. *AIDS* 2003;17:1179–1193.
- Grunfeld C, Kotler DP, Hamadeh R *et al.* Hypertriglyceridemia in the acquired immunodeficiency syndrome. *Am J Med* 1989;86:27–31.
- Fontas E, van Leth F, Sabin CA *et al.* Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? *J Infect Dis* 2004;189:1056–1074.
- Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of protease-inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance. *Lancet* 1998;351:1881–1883.
- Gan SK, Samaras K, Carr A, Chisholm DJ. Antiretroviral therapy, insulin resistance and lipodystrophy. *Diabetes Metab* 2001;3:67–71.
- Shlay JC, Bartsch G, Peng G *et al.* Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. *J Acquir Immune Defic Syndr* 2007;44:506–517.
- Lo JC, mUlligan K, Tai VW, Algren H, Schambelan M. Body shape changes in HIV-infected patients. *J Acquir Immune Defic Syndr Hum Retroviral* 1998;19:307–308.
- Mulligan K, Tai VW, Algren H *et al.* Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. *J Acquir Immune Defic Syndr* 2001;26:443–448.
- Wohl DA, McComsey G, Tebas P *et al.* Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. *Clin Infect Dis* 2006;43:645–653.
- Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. *Clin Infect Dis* 2002;34:248–259.
- Greenfield J, Samaras K, Jenkins AB *et al.* Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. *Circulation* 2004;109:3022–3028.
- Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999;340:115–126.
- Cao JJ, Arnold AM, Manolio TA *et al.* Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. *Circulation* 2007;116:32–38.
- Han TS, Sattar N, Williams K *et al.* Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. *Diabetes Care* 2002;25:2016–2021.
- Barzilay JI, Abraham L, Heckbert SR *et al.* The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. *Diabetes* 2001;50:2384–2389.
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* 2001;286:327–334.
- Pischon T, Girman CJ, Hotamisligil GS *et al.* Plasma adiponectin levels and the risk of myocardial infarction in men. *JAMA* 2004;291:1730–1737.
- Duncan BD, Schmidt MI, Pankow JS *et al.* Adiponectin and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. *Diabetes* 2004;53:2473–2478.

27. Samaras K, Wand H, Law M *et al.* Metabolic syndrome in HIV-infected patients using IDF and ATPIII criteria: prevalence, discordance and clinical utility. *Diabetes Care* 2007;30:113–119.
28. Estrada V, Martinez-Larrad MT, Gonzalez-Sanchez JL *et al.* Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. *Metabolism* 2006;55:940–945.
29. Jacobson DL, Tand AM, Spiegelman D *et al.* Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). *J Acquir Immune Deficiency Syndr* 2006;43:458–466.
30. Heilbronn KL, Gan N, Turner N, Campbell LV, Chisholm DJ. Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects. *J Clin Endocrinol Metab* 2007;92:1467–1473.
31. Peake PW, Kriketos AD, Campbell LV, Charlesworth JA. Response of the alternate complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. *Int J Obesity* 2005;29:429–435.
32. Koenig W, Sund M, Fröhlich M *et al.* C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. *Circulation* 1999;99:237–242.
33. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular event. *N Engl J Med* 2002;347:1557–1565.
34. Dolan SE, Hadigan C, Killilea KM *et al.* Increased cardiovascular disease risk indices in HIV-infected women. *J Acquir Immune Defic Syndr* 2005;39:44–54.
35. Furler SM, Gan SK, Poynten AM *et al.* Relationship of adiponectin with insulin sensitivity in humans, independent of lipid availability. *Obesity* 2006;14:228–234.
36. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. *Antivir Ther* 2003;8:9–15.
37. Tong Q, Sankale JL, Hadigan CM *et al.* Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. *J Clin Endocrinol Metab* 2003;88:1559–1564.
38. Mynarcik DC, Combs T, McNurian MA *et al.* Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. *J Acquir Immune Defic Syndr* 2002;315:14–20.
39. Jan V, Cervera P, Maachi M *et al.* Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. *Antivir Ther* 2004;9:555–564.
40. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. *J Clin Invest* 1995;240:9–15.
41. Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. *Diab Obes Metab* 2005;7:729–736.
42. Mynarcik DC, McNurian MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. *J Acquir Immune Defic Syndr* 2000;25:312–321.
43. Kotler DP, Ionescu G, Johnson JA *et al.* Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. *Clin Infect Dis* 2003;37(Suppl 2):S47–S51.
44. Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes mellitus. *J Clin Endocrinol Metab* 2002;87:1036–1040.